Malignant pleural mesothelioma is a uncommon and fast moving tumor where no successful treatment has been discovered in spite of the finding of quite a few probable genetic targets. The final stages of MPM diagnosis and the long latency that exists connects contacts and diagnosis have made it difficult to completely study the importance of risk factors and the resulting molecular effects.
Quite a few medical centers are witnessing an increasing amount of patients that are suffering from mesothelioma cancer. This gives pathologists diagnosing the patient many problems, which can be divided into those encountered in finding the differences between cancer of the mesothelium and harmless changes and those experienced in setting apart cancer of the mesothelium from additional forms of e-cadherin and tissue tumors that connect. Immunohistochemistry plays a major role in making the diagnosis, nevertheless it should be understood in regards to the experimental setting and radiological characteristics, and with a knowledge of the wide morphological variations existing in cancer of the mesothelium.
Cancer of the mesothelium is a primary cancer of the serosal cavities, an anatomic site that is also frequently affected by metastatic disease, mostly from primary carcinomas of the ovary, lung and breast. Progression in immunohistochemistry have caused an improvement in diagnostic sensitivity and specificity in the differential diagnosis in both cytological and histological material. Recently, the authors group employed high throughput technology to the recognition of new flags that may aid in differentiating cancer of the mesothelium from cancer in the peritoneum and ovaries, tumors with closely related histogenesis and antigenic profile. Together with the better tools available for cancer of the serosa diagnosis, realizing the biology of mesothelioma has been accumulating recently.